Advanced Medical Solutions Grp PLC Director/PDMR Shareholding (9237T)
22 Mars 2023 - 6:52PM
UK Regulatory
TIDMAMS
RNS Number : 9237T
Advanced Medical Solutions Grp PLC
22 March 2023
22 March 2023
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies ,
announces th at it was notified on 21 March 2023 that on 20 March
2023, a PCA of Liz Shanahan, Non-Executive Director, purchased
2,238 ordinary shares of 5p each ("Ordinary Shares") at a price of
222.8p per Ordinary Share and 2,206 Ordinary Shares at a price of
226.05p per Ordinary Share.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Timothy Lacey
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: PCA to Liz Shanahan, Non-Executive Director
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
* Purchase of Ordinary Shares
---------------------------------------------------------------------
c) Price(s) and volume(s):
Price(s) Volume(s)
Purchase of shares at 222.8p
per share 2,238
----------
Purchase of shares at 226.05p
per share 2,206
----------
---------------------------------------------------------------------
d) Aggregated information:
N/A
---------------------------------------------------------------------
e) Date of the transaction: 20/03/2023
---------------------------------------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
---------------------------------------------------------------------
- End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Matthew Neal / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Gary Clarence / David Anderson
HSBC Bank plc (Broker) Tel: 44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants;
Biomatlante, a French developer and manufacturer of surgical
biomaterials, Raleigh, a leading UK coater and converter of
woundcare and bio-diagnostics materials, AFS Medical, an Austrian
specialist surgical business and Connexicon, an Irish tissue
adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Ireland, Germany, France and Israel. Established in 1991,
the Group has more than 800 employees. For more
information, please see www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBRGDXCSDDGXD
(END) Dow Jones Newswires
March 22, 2023 13:52 ET (17:52 GMT)
Advanced Medical Solutions (AQSE:AMS.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Advanced Medical Solutions (AQSE:AMS.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024